CA2885240A1 - Novel mva virus and uses thereof - Google Patents
Novel mva virus and uses thereof Download PDFInfo
- Publication number
- CA2885240A1 CA2885240A1 CA2885240A CA2885240A CA2885240A1 CA 2885240 A1 CA2885240 A1 CA 2885240A1 CA 2885240 A CA2885240 A CA 2885240A CA 2885240 A CA2885240 A CA 2885240A CA 2885240 A1 CA2885240 A1 CA 2885240A1
- Authority
- CA
- Canada
- Prior art keywords
- amino acid
- gene product
- virus
- cell
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 240
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 claims abstract description 236
- 229960005486 vaccine Drugs 0.000 claims abstract description 63
- 238000000034 method Methods 0.000 claims abstract description 39
- 238000004519 manufacturing process Methods 0.000 claims abstract description 32
- 238000012258 culturing Methods 0.000 claims abstract description 28
- 206010046865 Vaccinia virus infection Diseases 0.000 claims abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
- 208000007089 vaccinia Diseases 0.000 claims abstract description 11
- 239000003085 diluting agent Substances 0.000 claims abstract description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 5
- 210000004027 cell Anatomy 0.000 claims description 430
- 239000000047 product Substances 0.000 claims description 279
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 238
- 150000001413 amino acids Chemical class 0.000 claims description 180
- 108090000623 proteins and genes Proteins 0.000 claims description 149
- 230000004048 modification Effects 0.000 claims description 144
- 238000012986 modification Methods 0.000 claims description 144
- 150000007523 nucleic acids Chemical group 0.000 claims description 143
- 101150085281 A3L gene Proteins 0.000 claims description 140
- 101150096528 A9L gene Proteins 0.000 claims description 134
- 101150049392 A34R gene Proteins 0.000 claims description 132
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 128
- 230000035772 mutation Effects 0.000 claims description 96
- 150000001875 compounds Chemical class 0.000 claims description 59
- 239000002609 medium Substances 0.000 claims description 38
- 238000012217 deletion Methods 0.000 claims description 35
- 230000037430 deletion Effects 0.000 claims description 35
- 102000004169 proteins and genes Human genes 0.000 claims description 35
- 241000271566 Aves Species 0.000 claims description 34
- 101100350652 Vaccinia virus (strain Western Reserve) VACWR122 gene Proteins 0.000 claims description 34
- 230000001464 adherent effect Effects 0.000 claims description 34
- 239000000427 antigen Substances 0.000 claims description 30
- 108091007433 antigens Proteins 0.000 claims description 30
- 102000036639 antigens Human genes 0.000 claims description 30
- 230000010076 replication Effects 0.000 claims description 28
- 101150115056 A31R gene Proteins 0.000 claims description 25
- 101100000228 Vaccinia virus (strain Western Reserve) VACWR157 gene Proteins 0.000 claims description 25
- 108020004707 nucleic acids Proteins 0.000 claims description 22
- 102000039446 nucleic acids Human genes 0.000 claims description 22
- 230000001225 therapeutic effect Effects 0.000 claims description 22
- 102220603448 Homeobox protein SIX3_A34R_mutation Human genes 0.000 claims description 21
- 239000006228 supernatant Substances 0.000 claims description 20
- 102220005376 rs33915947 Human genes 0.000 claims description 19
- 230000004663 cell proliferation Effects 0.000 claims description 18
- 239000013587 production medium Substances 0.000 claims description 18
- 102200026258 rs28929484 Human genes 0.000 claims description 15
- 239000000725 suspension Substances 0.000 claims description 15
- 238000002255 vaccination Methods 0.000 claims description 15
- 102220311820 rs1376867262 Human genes 0.000 claims description 14
- 241000288906 Primates Species 0.000 claims description 13
- 230000002209 hydrophobic effect Effects 0.000 claims description 10
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- 230000006801 homologous recombination Effects 0.000 claims description 5
- 238000002744 homologous recombination Methods 0.000 claims description 5
- 210000005260 human cell Anatomy 0.000 claims description 5
- 239000013592 cell lysate Substances 0.000 claims description 4
- 102220179791 rs752964419 Human genes 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 description 55
- 241000272525 Anas platyrhynchos Species 0.000 description 36
- 230000002458 infectious effect Effects 0.000 description 34
- 238000004113 cell culture Methods 0.000 description 31
- 241000282414 Homo sapiens Species 0.000 description 28
- 241001465754 Metazoa Species 0.000 description 28
- 238000002474 experimental method Methods 0.000 description 27
- 241000287828 Gallus gallus Species 0.000 description 25
- 230000002238 attenuated effect Effects 0.000 description 24
- 101100489783 Vaccinia virus (strain Ankara) MVA120L gene Proteins 0.000 description 23
- 101100489785 Vaccinia virus (strain Western Reserve) VACWR128 gene Proteins 0.000 description 23
- 238000004114 suspension culture Methods 0.000 description 21
- 230000008569 process Effects 0.000 description 20
- 108020004414 DNA Proteins 0.000 description 19
- 241000725303 Human immunodeficiency virus Species 0.000 description 18
- 238000003780 insertion Methods 0.000 description 17
- 230000037431 insertion Effects 0.000 description 17
- 210000001525 retina Anatomy 0.000 description 17
- 206010028980 Neoplasm Diseases 0.000 description 16
- 230000006229 amino acid addition Effects 0.000 description 16
- 238000002955 isolation Methods 0.000 description 15
- 241000272814 Anser sp. Species 0.000 description 14
- 241000286209 Phasianidae Species 0.000 description 14
- 230000036039 immunity Effects 0.000 description 14
- 230000028993 immune response Effects 0.000 description 13
- 230000001965 increasing effect Effects 0.000 description 12
- 210000004379 membrane Anatomy 0.000 description 12
- 239000012528 membrane Substances 0.000 description 12
- 230000001413 cellular effect Effects 0.000 description 11
- 239000006166 lysate Substances 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 230000001681 protective effect Effects 0.000 description 11
- 238000012163 sequencing technique Methods 0.000 description 11
- 238000000746 purification Methods 0.000 description 10
- 210000002023 somite Anatomy 0.000 description 10
- 241000711950 Filoviridae Species 0.000 description 9
- 241000710831 Flavivirus Species 0.000 description 9
- 241000711549 Hepacivirus C Species 0.000 description 9
- 241000150452 Orthohantavirus Species 0.000 description 9
- 241000700618 Vaccinia virus Species 0.000 description 9
- 230000003321 amplification Effects 0.000 description 9
- 238000010171 animal model Methods 0.000 description 9
- 230000003115 biocidal effect Effects 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 9
- 208000006454 hepatitis Diseases 0.000 description 9
- 231100000283 hepatitis Toxicity 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 238000003199 nucleic acid amplification method Methods 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 241000712461 unidentified influenza virus Species 0.000 description 9
- 210000002845 virion Anatomy 0.000 description 9
- 230000003612 virological effect Effects 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 241000272834 Cairina moschata Species 0.000 description 7
- 230000009286 beneficial effect Effects 0.000 description 7
- 229960000074 biopharmaceutical Drugs 0.000 description 7
- 230000000120 cytopathologic effect Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 210000002950 fibroblast Anatomy 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 210000000987 immune system Anatomy 0.000 description 7
- 210000004962 mammalian cell Anatomy 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 238000004448 titration Methods 0.000 description 7
- 229920000936 Agarose Polymers 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 238000004115 adherent culture Methods 0.000 description 6
- 230000031018 biological processes and functions Effects 0.000 description 6
- 108091092356 cellular DNA Proteins 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 210000001161 mammalian embryo Anatomy 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 238000004062 sedimentation Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 108700026758 Adenovirus hexon capsid Proteins 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 5
- 101150029707 ERBB2 gene Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 108010008707 Mucin-1 Proteins 0.000 description 5
- 102100034256 Mucin-1 Human genes 0.000 description 5
- 230000006978 adaptation Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000013553 cell monolayer Substances 0.000 description 5
- 235000013399 edible fruits Nutrition 0.000 description 5
- 210000001723 extracellular space Anatomy 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 230000035800 maturation Effects 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000007704 transition Effects 0.000 description 5
- 230000029812 viral genome replication Effects 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 206010061598 Immunodeficiency Diseases 0.000 description 4
- 108700026244 Open Reading Frames Proteins 0.000 description 4
- 241000289054 Rousettus aegyptiacus Species 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 238000009833 condensation Methods 0.000 description 4
- 230000005494 condensation Effects 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- 239000000356 contaminant Substances 0.000 description 4
- 235000013601 eggs Nutrition 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000001506 immunosuppresive effect Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 108090000204 Dipeptidase 1 Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 238000012286 ELISA Assay Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010025815 Kanamycin Kinase Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229930193140 Neomycin Natural products 0.000 description 3
- 101710172711 Structural protein Proteins 0.000 description 3
- 108010015780 Viral Core Proteins Proteins 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000003266 anti-allergic effect Effects 0.000 description 3
- 230000000843 anti-fungal effect Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 102000006635 beta-lactamase Human genes 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000002051 biphasic effect Effects 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000003927 comet assay Methods 0.000 description 3
- 231100000170 comet assay Toxicity 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 3
- 238000000799 fluorescence microscopy Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 238000009776 industrial production Methods 0.000 description 3
- 238000013383 initial experiment Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 229960004927 neomycin Drugs 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000002864 sequence alignment Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 230000008467 tissue growth Effects 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 210000003501 vero cell Anatomy 0.000 description 3
- 230000001018 virulence Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 108091093088 Amplicon Proteins 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 108091033380 Coding strand Proteins 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 2
- 241000991587 Enterovirus C Species 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 241001364432 Microbates Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000282339 Mustela Species 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 241000700647 Variola virus Species 0.000 description 2
- 108020005202 Viral DNA Proteins 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000012863 analytical testing Methods 0.000 description 2
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 108091092328 cellular RNA Proteins 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000008450 motivation Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 241000191985 Anas superciliosa Species 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000710188 Encephalomyocarditis virus Species 0.000 description 1
- 238000005773 Enders reaction Methods 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000941423 Grom virus Species 0.000 description 1
- 241000941424 Hermitage virus Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 241000883510 Kolla Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 241000219745 Lupinus Species 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 101100346932 Mus musculus Muc1 gene Proteins 0.000 description 1
- 241000700629 Orthopoxvirus Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000700625 Poxviridae Species 0.000 description 1
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 101100269369 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) AGE1 gene Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000008049 TAE buffer Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 229940124928 YF-Vax Drugs 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- HGEVZDLYZYVYHD-UHFFFAOYSA-N acetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound CC(O)=O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O HGEVZDLYZYVYHD-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229960004977 anhydrous lactose Drugs 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000531 effect on virus Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 244000144992 flock Species 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 229940029583 inactivated polio vaccine Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229940024231 poxvirus vaccine Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012372 quality testing Methods 0.000 description 1
- 230000003134 recirculating effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
- 238000012070 whole genome sequencing analysis Methods 0.000 description 1
- 239000012130 whole-cell lysate Substances 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24061—Methods of inactivation or attenuation
- C12N2710/24064—Methods of inactivation or attenuation by serial passage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2012/069256 WO2014048500A1 (en) | 2012-09-28 | 2012-09-28 | Novel mva virus and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2885240A1 true CA2885240A1 (en) | 2014-04-03 |
Family
ID=46982581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2885240A Abandoned CA2885240A1 (en) | 2012-09-28 | 2012-09-28 | Novel mva virus and uses thereof |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9732325B2 (enExample) |
| EP (1) | EP2900810B1 (enExample) |
| JP (1) | JP2015535687A (enExample) |
| CN (1) | CN104812894B (enExample) |
| AU (1) | AU2012391162A1 (enExample) |
| BR (1) | BR112015006798A2 (enExample) |
| CA (1) | CA2885240A1 (enExample) |
| DK (1) | DK2900810T3 (enExample) |
| IN (1) | IN2015DN02335A (enExample) |
| MX (1) | MX2015003687A (enExample) |
| RU (1) | RU2015115898A (enExample) |
| WO (1) | WO2014048500A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3585882A1 (en) * | 2017-02-23 | 2020-01-01 | ProBioGen AG | Novel vaccinia virus vectors related to mva with extensive genomic symmetries |
| WO2019089755A1 (en) | 2017-10-31 | 2019-05-09 | Western Oncolytics Ltd. | Platform oncolytic vector for systemic delivery |
| CN108371715A (zh) * | 2018-01-03 | 2018-08-07 | 肖小林 | 一种病毒的靶向性防治药物 |
| CN112512569A (zh) * | 2018-05-11 | 2021-03-16 | 希望之城 | 表达多个巨细胞病毒(cmv)抗原的mva载体及其用途 |
| CA3104392A1 (en) | 2018-07-04 | 2020-01-09 | Probiogen Ag | Method for purifying an enveloped virus |
| JP2023552289A (ja) | 2020-11-19 | 2023-12-15 | カリヴィル イムノセラピューティクス， インコーポレイテッド | 腫瘍微小環境リモデリングによる腫瘍溶解性免疫療法 |
| KR102963059B1 (ko) | 2021-12-29 | 2026-05-11 | 재단법인 아산사회복지재단 | 외피외 바이러스 생산이 증가한 신규한 백시니아 바이러스 변이주 |
| WO2023128672A1 (ko) * | 2021-12-29 | 2023-07-06 | 재단법인 아산사회복지재단 | 외피외 바이러스 생산이 증가한 신규한 백시니아 바이러스 변이주 |
| WO2023223183A1 (en) | 2022-05-16 | 2023-11-23 | Crispr Therapeutics Ag | Picornaviral vectors for gene editing |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7645456B2 (en) * | 2001-04-23 | 2010-01-12 | Sanofi Pasteur Biologics Co. | Vaccinia virus strains |
| JP5052893B2 (ja) | 2003-02-20 | 2012-10-17 | アメリカ合衆国 | ポックスベクターにおける新規の挿入部位 |
-
2012
- 2012-09-28 IN IN2335DEN2015 patent/IN2015DN02335A/en unknown
- 2012-09-28 RU RU2015115898A patent/RU2015115898A/ru not_active Application Discontinuation
- 2012-09-28 JP JP2015533460A patent/JP2015535687A/ja active Pending
- 2012-09-28 US US14/431,814 patent/US9732325B2/en active Active
- 2012-09-28 EP EP12769398.4A patent/EP2900810B1/en active Active
- 2012-09-28 WO PCT/EP2012/069256 patent/WO2014048500A1/en not_active Ceased
- 2012-09-28 BR BR112015006798A patent/BR112015006798A2/pt not_active IP Right Cessation
- 2012-09-28 CA CA2885240A patent/CA2885240A1/en not_active Abandoned
- 2012-09-28 CN CN201280077370.4A patent/CN104812894B/zh active Active
- 2012-09-28 DK DK12769398.4T patent/DK2900810T3/en active
- 2012-09-28 MX MX2015003687A patent/MX2015003687A/es unknown
- 2012-09-28 AU AU2012391162A patent/AU2012391162A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014048500A1 (en) | 2014-04-03 |
| DK2900810T3 (en) | 2019-04-29 |
| EP2900810A1 (en) | 2015-08-05 |
| BR112015006798A2 (pt) | 2017-11-21 |
| US20150299666A1 (en) | 2015-10-22 |
| MX2015003687A (es) | 2015-06-15 |
| IN2015DN02335A (enExample) | 2015-08-28 |
| EP2900810B1 (en) | 2019-02-20 |
| RU2015115898A (ru) | 2016-11-20 |
| US9732325B2 (en) | 2017-08-15 |
| CN104812894B (zh) | 2021-10-22 |
| AU2012391162A1 (en) | 2015-04-09 |
| JP2015535687A (ja) | 2015-12-17 |
| CN104812894A (zh) | 2015-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9732325B2 (en) | MVA virus and uses thereof | |
| JP5783642B2 (ja) | Ｍｖａの主なゲノム欠失を含むワクシニアウイルス変異体 | |
| TW575664B (en) | Recombinant MVA virus, and the use thereof | |
| JP2010259446A (ja) | ポックスウイルスゲノムに挿入された相同遺伝子を発現させる組換えポックスウイルス | |
| BRPI0215003B1 (pt) | método para a recuperação e purificação de poxvírus a partir de células infectadas | |
| Léon et al. | The EB66® cell line as a valuable cell substrate for MVA-based vaccines production | |
| CN103088049A (zh) | 日本脑炎病毒sa14-14-2株基于dna的感染性克隆、其构建方法及应用 | |
| Jordan et al. | A chemically defined production process for highly attenuated poxviruses | |
| US11999975B2 (en) | Method for purifying an enveloped virus | |
| CN1723285B (zh) | 重组的mva及其产生方法 | |
| Melamed et al. | Attenuation and immunogenicity of host-range extended modified vaccinia virus Ankara recombinants | |
| US11104884B2 (en) | Vaccinia virus vectors related to MVA with extensive genomic symmetries | |
| WO2004087047A2 (en) | Mutants of replication competent vaccinia virus | |
| JP2006509526A (ja) | トリ胚性幹細胞上におけるａｌｖａｃの産生 | |
| KR20250156704A (ko) | 메추라기 세포 배양을 통한 폭스바이러스 생산 | |
| WO2024188801A1 (en) | Use of quail cell lines for poxvirus production | |
| AU2024280931A9 (en) | Rapid selection system for the generation of recombinant enveloped viruses | |
| WO2024245721A1 (en) | Diploid recombinant nucleocytoplasmic large dna viral vectors | |
| Ricci | Generation of modified vaccinia virus ankara recombinants by rescue of the essential D4R gene | |
| EP2199385A1 (en) | Specific and persistent activation of heat shock response in cell lines using a viral factor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20180928 |